

Express Mail Label No.:  
Date of Deposit: April 22, 2002

Attorney Docket No. 21415-501

#12  
B  
4/59/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Sarah Ferber

SERIAL NUMBER: 09/584,216

EXAMINER: Voitach, Joseph T.

FILING DATE: May 31, 2000

ART UNIT: 1632

FOR: METHODS OF INDUCING REGULATED PANCREATIC HORMONE  
PRODUCTION IN NON-PANCREATIC ISLET TISSUES

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Prior to examination of the above-identified application, please amend the application as set forth below.

***In the Specification:***

On page 6, please replace the paragraph beginning on line 18 with the following rewritten paragraph.

B1

In another aspect, the method includes providing a cell from a subject, contacting the cell with a compound which increases PDX expression in an amount sufficient to increase pancreatic hormone production and introducing the cell into a subject. In one embodiment pancreatic hormone production occurs *in-vitro* and *in-vivo*, upon introducing the cell into the subject. In an alternative embodiment, pancreatic hormone production occurs *in-vivo* upon introducing the cell in the subject.

On page 11, replace the paragraph beginning on line 1 with the following rewritten paragraph.

B2

By "pancreatic islet cell phenotype" is meant that the cell displaying one or more characteristics typical of pancreatic islet cells, *i.e.* hormone production, processing, storage in secretory granules, nutritionally and hormonally regulated secretion or characteristic islet cell gene expression profile. The pancreatic islet cell phenotype can be determined for example by measuring pancreatic hormone production, *e.g.*, insulin, somatostatin or glucagon. Hormone production can be determined by methods known in the art, *e.g.* immunoassay, western blot,